https://orcid.org/0000-0002-9140-4603
References
- Brodmann M, Zeller T, Christensen J, et al. Real-world experience with a Paclitaxel-Coated Balloon for the treatment of atherosclerotic infrainguinal arteries: 12-month interim results of the BIOLUX P-III registry first year of enrolment. J Vasc Bras. 2017;16(4):276–284. doi:10.1590/1677-5449.00731729930661
- Cronenwett JL, Johnston KW. Rutherford’s Vascular Surgery E-Book. Elsevier Health Sciences; 2014.
- Katsanos K, Spiliopoulos S, Kitrou P, Krokidis M, Karnabatidis D. Risk of death following application of paclitaxel‐coated balloons and stents in the femoropopliteal artery of the leg: a systematic review and meta‐analysis of randomized controlled trials. J Am Heart Assoc. 2018;7(24):e011245. doi:10.1161/JAHA.118.01124530561254
- Scheinert D, Duda S, Zeller T, et al. The LEVANT I (Lutonix paclitaxel-coated balloon for the prevention of femoropopliteal restenosis) trial for femoropopliteal revascularization: first-in-human randomized trial of low-dose drug-coated balloon versus uncoated balloon angioplasty. JACC Cardiovasc Interv. 2014;7(1):10–19. doi:10.1016/j.jcin.2013.05.02224456716
- Werk M, Langner S, Reinkensmeier B, et al. Inhibition of restenosis in the femoropopliteal arteries. Aha J. 2008;13(118):1358–1365.
- Laird JR, Schneider PA, Tepe G, et al. Durability of treatment effect using a drug-coated balloon for femoropopliteal lesions: 24-month results of IN. PACT SFA. J Am Coll Cardiol. 2015;66(21):2329–2338. doi:10.1016/j.jacc.2015.09.06326476467
- Rosenfield K, Jaff MR, White CJ, et al. Trial of a paclitaxel-coated balloon for femoropopliteal artery disease. N Engl J Med. 2015;373(2):145–153. doi:10.1056/NEJMoa140623526106946
- Schroeder H, Meyer DR, Lux B, Ruecker F, Martorana M, Duda S. Two‐year results of a low‐dose drug‐coated balloon for revascularization of the femoropopliteal artery: outcomes from the ILLUMENATE first‐in‐human study. Catheter Cardiovasc Interv. 2015;86(2):278–286. doi:10.1002/ccd.2590025708850
- Schroeder H, Werner M, Meyer D-R, et al. Low-dose paclitaxel–coated versus uncoated percutaneous transluminal balloon angioplasty for femoropopliteal peripheral artery disease: one-year results of the ILLUMENATE European randomized clinical trial (Randomized trial of a novel paclitaxel-coated percutaneous angioplasty balloon). Circulation. 2017;135(23):2227–2236. doi:10.1161/CIRCULATIONAHA.116.02649328424223
- Sridharan ND, Boitet A, Smith K, et al. Cost-effectiveness analysis of drug-coated therapies in the superficial femoral artery. J Vasc Surg. 2018;67(1):343–352. doi:10.1016/j.jvs.2017.06.11228958476